P
Patrick J. Commerford
Researcher at University of Cape Town
Publications - 97
Citations - 15286
Patrick J. Commerford is an academic researcher from University of Cape Town. The author has contributed to research in topics: Atrial fibrillation & Myocardial infarction. The author has an hindex of 38, co-authored 94 publications receiving 13648 citations. Previous affiliations of Patrick J. Commerford include Groote Schuur Hospital & University of Texas System.
Papers
More filters
Journal ArticleDOI
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study.
Salim Yusuf,Steven Hawken,Stephanie Ôunpuu,Leonelo E. Bautista,Maria Grazia Franzosi,Patrick J. Commerford,Chim C. Lang,Zvonko Rumboldt,Churchill L. Onen,Liu Lisheng,Supachai Tanomsup,Paul Wangai,Fahad Razak,Arya M. Sharma,Sonia S. Anand +14 more
TL;DR: Redefinition of obesity based on waist-to-hip ratio instead of BMI increases the estimate of myocardial infarction attributable to obesity in most ethnic groups.
Journal ArticleDOI
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly,John W. Eikelboom,Campbell D. Joyner,Hans-Christoph Diener,Robert G. Hart,Sergey P. Golitsyn,Greg C. Flaker,Alvaro Avezum,Stefan H. Hohnloser,Rafael Diaz,Mario Talajic,Jun Zhu,Prem Pais,Andrzej Budaj,Alexander Parkhomenko,Petr Jansky,Patrick J. Commerford,Ru San Tan,Kui-Hian Sim,Basil S. Lewis,Walter Van Mieghem,Jae Hyung Kim,Fernando Lanas-Zanetti,Antonio Gonzalez-Hermosillo,Antonio L. Dans,Muhammad Munawar,John H. Lawrence,Gayle Lewis,Rizwan Afzal,Salim Yusuf +29 more
TL;DR: In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage.
Journal ArticleDOI
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom,Stuart J. Connolly,Jackie Bosch,Gilles R. Dagenais,Robert G. Hart,Olga Shestakovska,Rafael Diaz,Marco Alings,Eva Lonn,Sonia S. Anand,Petr Widimsky,Masatsugu Hori,Alvaro Avezum,Leopoldo S. Piegas,Kelley R. Branch,Jeffrey L. Probstfield,Deepak L. Bhatt,Jun Zhu,Yan Liang,Aldo P. Maggioni,Patricio Lopez-Jaramillo,Martin O'Donnell,Ajay K. Kakkar,Keith A.A. Fox,Alexander Parkhomenko,Georg Ertl,Stefan Störk,Matyas Keltai,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Peter Verhamme,Dragos Vinereanu,Jae-Hyung Kim,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,P. Gabriel Steg,Kaj Metsärinne,Nancy Cook Bruns,Frank Misselwitz,Edmond Chen,Darryl P. Leong,Salim Yusuf +48 more
TL;DR: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
Journal ArticleDOI
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
Stuart J. Connolly,Janice Pogue,John W. Eikelboom,Gregory C. Flaker,Patrick J. Commerford,Maria Grazia Franzosi,Jeff S. Healey,Salim Yusuf +7 more
TL;DR: For centers and countries, a target threshold TTR exists (estimated between 58% and 65%) below which there appears to be little benefit of OAC over antiplatelet therapy, and a wide variation exists in international normalized ratio control, as measured by TTR, between clinical centers and between countries.
Journal ArticleDOI
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker,Jean G. MacFadyen,Tom Thuren,Brendan M. Everett,Peter Libby,R J Glynn,Paul Ridker,Alberto J. Lorenzatti,Henry Krum,John Varigos,Peter Siostrzonek,Peter Sinnaeve,Francisco Antonio Helfenstein Fonseca,Jose C. Nicolau,Nina Gotcheva,Jacques Genest,Huo Yong,Miguel Urina-Triana,Davor Miličić,Renata Cifkova,Riina Vettus,Wolfgang Koenig,Stephan D Anker,Athanasios J. Manolis,Fernando Wyss,Tamás Forster,Axel Sigurdsson,Prem Pais,Alessandro Fucili,Hisao Ogawa,Hiroaki Shimokawa,Irina Veze,Birute Petrauskiene,Leon Salvador,John J.P. Kastelein,Jan H. Cornel,Tor Ole Klemsdal,Félix Medina,Andrzej Budaj,Luminita Vida-Simiti,Zhanna Kobalava,Petar Otasevic,Daniel Pella,Mitja Lainscak,Ki-Bae Seung,Patrick J. Commerford,Mikael Dellborg,Marc Y. Donath,Juey-Jen Hwang,Hakan Kultursay,Marcus Flather,Christie M. Ballantyne,Seth Bilazarian,William Chang,Cara East,Brendan Everett,Les Forgosh,Robert J. Glynn,Barry Harris,Monica Ligueros,Erin A. Bohula,Bindu Charmarthi,Susan Cheng,Sherry Chou,Jacqueline Danik,Graham McMahon,Bradley Maron,MingMing Ning,Benjamin Olenchock,Reena Pande,Todd Perlstein,Aruna D. Pradhan,Natalia Rost,Aneesh Singhal,Viviany Taqueti,Nancy Wei,Howard A. Burris,Angela Cioffi,Anne Marie Dalseg,Nilanjan Ghosh,Julie R. Gralow,Tina Mayer,Hope S. Rugo,Vance G. Fowler,Ajit P. Limaye,Sara Cosgrove,Donald Levine,Renato D. Lopes,John D. Scott,Robert Hilkert,Georgia Tamesby,Carolyn Mickel,Brian Manning,Julian Woelcke,Monique Tan,Sheryl Manfreda,Tom Ponce,Jane Kam,Ravinder Saini,Kehur Banker,Thomas Salko,Panjat Nandy,Ronda Tawfik,Greg O'Neil,Shobha Manne,Pravin Jirvankar,Shankar Lal,Deepak Nema,Jaison Jose,Rory Collins,Kent Bailey,Roger S. Blumenthal,Helen M. Colhoun,Bernard J. Gersh +113 more
TL;DR: The hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality.